Skip to main content
MEDS logo

DataMEDS AI, Inc. (MEDS) Stock Price & Analysis

DataMEDS AI, Inc. (MEDS) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $1.34 (+84.14%), as of the Nov 20, 2026 trading session; market cap $7.67M.

Educational signal · not a buy or sell recommendation · How to read this

$1.34 +$0.6123 (+84.14%) Market Cap $7.67M

DataMEDS AI, Inc. · MEDS · NASDAQ

TRxADE HEALTH, Inc. operates as a healthcare technology firm, modernizing retail pharmacy through its TRxADE marketplace for drug acquisition and its Bonum Health brand for patient-centric telehealth services.

Price as of Nov 20, 2026

Key Statistics

19 of 100

MoonshotScore v2 · DataMEDS AI (MEDS)

Weak
Business Quality Poor (11)
Financial Safety Okay (41)
Valuation Bubble (2)
Growth Durability Shrinking (4)
Momentum Falling (15)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, stalling growth and an expensive valuation, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $3M (Q3 FY2025, quarter ended Sep 2025)
  • Altman Z -7.83 · Piotroski F 2

Holding back: weak fundamentals, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MEDS (58 recorded, newest six shown)
RecordedScoreBand
18Weak
19Weak
19Weak
19Weak
19Weak
19Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.34
Change on the day+84.14%
Market capitalisation$7.67M—
Shares traded on the day89.98M

Price & events

Other perspectives

Council score for DataMEDS AI (MEDS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Negative
Growth Durability Negative
Momentum Negative

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Gross Margin Negative

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is DataMEDS AI (MEDS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. DataMEDS AI, Inc. (MEDS) is listed on NASDAQ. In Q3 FY2025 it reported revenue of $3M and net income of -$34M. The market values it at $7.67M.

2 · Latest results

What do the latest results show for DataMEDS AI (MEDS)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $3M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$3M-$34M-$23.07 (diluted)
Q4 FY2025$2M-$28M—
Q1 FY2026$2M-$8M-$3.70 (diluted)
Q2 FY2026$2M-$18M-$7.13 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for DataMEDS AI (MEDS)?

Short answer · as of

What is holding it back is weak fundamentals, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -7.83 · Piotroski F 2. Trailing ratios: ROA -82.9% · current ratio 0.14.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -7.83 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does DataMEDS AI compare with its peers?

Short answer

DataMEDS AI's score ranks 8th of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Guardian Pharmacy Services, Inc. (GRDN) Same industry, near in market value$46.94 Nov 20, 2026$2.97B96 5-pillar Nov 18, 2026
McKesson Corporation (MCK) Same industry, near in market value$1069.43 Nov 20, 2026$123B92 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Same industry, near in market value$272.93 Nov 20, 2026$63.1B88 5-pillar Nov 18, 2026
Cencora, Inc. (COR) Same industry, near in market value$339.09 Nov 20, 2026$64.7B86 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Same industry, near in market value$83.52 Nov 20, 2026$9.23B73 5-pillar Nov 18, 2026
Prestige Consumer Healthcare Inc. (PBH) Same industry, near in market value$49.63 Nov 20, 2026$2.35B63 5-pillar Nov 18, 2026
Accendra Health, Inc. (ACH) Same industry, near in market value$0.09 Nov 19, 2026$6.60M30 5-pillar Nov 18, 2026
DataMEDS AI (MEDS) — this page$1.34$7.67M19

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 22, 2026

Transactions
4
Identified insiders
2
Purchases
0
Sales
0
Other transactions
4

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MEDS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MEDS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about DataMEDS AI (MEDS)?

Read these with our analysis →

DataMEDS AI Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the MEDS research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MEDS?

MEDS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is MEDS a good stock to buy?

Stock Expert AI does not rate MEDS buy, sell or hold. DataMEDS AI, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MEDS stock price today?

The last price recorded for DataMEDS AI, Inc. (MEDS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What revenue streams does TRxADE HEALTH, Inc. have in healthcare?

TRxADE HEALTH, Inc. generates revenue primarily through two distinct healthcare technology segments. The first stream comes from its TRxADE marketplace, which facilitates the procurement of pharmaceutical products.

What are the key factors to evaluate for MEDS?

DataMEDS AI, Inc. (MEDS) holds a MoonshotScore in the low range. Not financial advice.

How frequently does MEDS data refresh on this page?

MEDS's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MEDS's recent stock price performance?

DataMEDS AI, Inc. (MEDS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MEDS overvalued or undervalued right now?

DataMEDS AI, Inc. (MEDS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of MEDS?

Fractional-share availability for DataMEDS AI, Inc. (MEDS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.